NL-OMON28674尚未招募不适用
Pharmacokinetics of nasally administered tobramycin and colistin in Cystic Fibrosis
none0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Confirmed diagnosis of Cystic Fibrosis based on genotyping or a positive sweat test;
- •- Age > 18 years;
排除标准
- •- Kidney dysfunction (defined as estimated Glomerular Filtration Rate of < 50 ml/min);
- •- Liver dysfunction (defined as at least one of the following enzymes ¡Ý 3 times the normal value; aspartate aminotransferase (ASAT), alanin aminotransferase (ALAT), Gamma-glutamyltransferase (gGT), lactate dehydrogenase (LD) and alkaline phosphatase (ALP);
研究者
相似试验
已完成
不适用
Pharmacokinetics of nasally administered tobramycin and colistin in Cystic FibrosisCystic Fibrosis100386861000401810024970mucoviscidosisNL-OMON38737HagaZiekenhuis10
已完成
1 期
Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic StudyCystic FibrosisNCT00420836Novartis20
已完成
1 期
Tobramycin Administered at the Beginning of DialysisRenal DialysisRenal Failure, ChronicNCT03904836Maisonneuve-Rosemont Hospital11
已完成
不适用
Tobramycin nebulisation with I-neb (TONI) study in children with cystic fibrosis: pharmacokinetics and safety'Cystic Fibrosis' en 'CF'100836241000401810024970NL-OMON39647Erasmus MC, Universitair Medisch Centrum Rotterdam24
进行中（未招募）
不适用
Tobramycin nebulisation with I-neb (TONI) study in children with cystic fibrosis: pharmacokinetics and safetyMedDRA version: 14.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic fibrosisEUCTR2012-002503-17-NLErasmus University Medical Centre